Nandrolone and Trenbolone Interaction: Avoid | Peptide Database

Join others researching Dapoxetine — share findings, ask questions, and learn from real experiences Dapoxetine is the first and only selective serotonin reuptake inhibitor (SSRI) specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64. Unlike conventional SSRIs such as paroxetine or sertraline -- which are sometimes used off-label for PE but require daily dosing and weeks to reach therapeutic effect -- dapoxetine was engineered for rapid absorption and short elimination, making it suitable for as-needed use 1-3 hours before sexual activity. Originally developed by Eli Lilly and later licensed to Johnson & Johnson (ALZA Corporation), dapoxetine received its first regulatory approval in Sweden in 2009 under the brand name Priligy, and has since been approved in over 50 countries across Europe, Asia, Latin America, and the Middle East. It has not received FDA approval in the United States despite multiple submissions. Dapoxetine works by increasing serotonin activity at the postsynaptic cleft in the ejaculatory reflex pathway, raising the threshold for ejaculation and improving control over the timing of climax. Dapoxetine selectively inhibits the serotonin transporter (SERT) at presynaptic nerve terminals, blocking reuptake of serotonin (5-HT) from the synaptic cleft. This increases serotonin concentration at postsynaptic receptors in the neural circuits governing the ejaculatory reflex, particularly within the spinal ejaculation generator and supraspinal pathways. The ejaculatory process is modulated by serotonergic neurotransmission: higher serotonin levels at 5-HT1B and 5-HT2C receptors raise the ejaculatory threshold, delaying the emission and expulsion phases of ejaculation. Unlike traditional SSRIs that require 1-2 weeks of daily dosing to achieve steady-state serotonin levels, dapoxetine reaches peak plasma concentration within approximately 1-2 hours after oral administration and is rapidly eliminated (terminal half-life ~1.5 hours, with an initial half-life of ~1.4 hours). This pharmacokinetic profile enables acute, on-demand modulation of serotonergic tone without the sustained receptor desensitization seen with chronic SSRI use.

RAD-140 has shown potent anabolic effects on skeletal muscle in preclinical models, with increases in lean body mass comparable to moderate doses of testosterone. Users report meaningful increases in lean mass over 8-12 week cycles at 10-20 mg/day, though controlled human trial data for this indication is lacking. Dose-dependent increases in strength have been reported anecdotally and are consistent with the compound's mechanism of action as a potent AR agonist in skeletal muscle. Strength gains are typically noticed within 2-4 weeks of starting a cycle. The combination of anabolic activity without estrogenic water retention makes RAD-140 a compound of interest for simultaneous fat loss and lean mass gain. Preclinical data supports a favorable shift in body composition, though human data is limited. RAD-140 has entered Phase 1 clinical trials for the treatment of ER+/AR+/HER2- metastatic breast cancer. The rationale is that AR activation can suppress estrogen-driven tumor growth in AR-positive breast cancers. Early results demonstrated tolerability and preliminary signals of anti-tumor activity. Originally developed for conditions involving muscle wasting (cachexia, sarcopenia, age-related muscle loss). Preclinical data supports the potential to preserve or restore muscle mass in catabolic states, but no human efficacy trials have been completed for this indication. In vitro studies have shown that RAD-140 protects hippocampal neurons from kainate-induced excitotoxicity and beta-amyloid-induced cell death, suggesting potential relevance to neurodegenerative diseases. This remains a preclinical observation only.